Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study

BACKGROUND: The presence of pleural effusion is an independent predictor for poor survival in patients with small‐cell lung cancer (SCLC). The aim of this study was to assess the efficacy and safety of anlotinib in patients with SCLC and pleural effusion. METHODS: This was a randomized, double‐blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Cheng, Ying, Wang, Qiming, Li, Kai, Shi, Jianhua, Wu, Lin, Han, Baohui, Chen, Gongyan, He, Jianxing, Wang, Jie, Qin, Haifeng, Li, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590889/
https://www.ncbi.nlm.nih.gov/pubmed/34596367
http://dx.doi.org/10.1111/1759-7714.14176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590889/
https://www.ncbi.nlm.nih.gov/pubmed/34596367
http://dx.doi.org/10.1111/1759-7714.14176

Ejemplares similares